Peters-Engl C, Medl M, Ogris E, Leodolter S
Department of Gynecology and Obstetrics, Lainz Medical Center, Vienna, Austria.
Anticancer Res. 1995 Nov-Dec;15(6B):2727-30.
In 180 patients with epithelial ovarian cancer and 214 women with benign pelvic pathologies, serum levels of TATI (cut-off point 21 ng ml-1) and CA 125 (cut-off point 35 U ml-1) were determined. Data were correlated with tumour stage, histological type and tumour grade. Overall, when used as a single marker, TATI showed a sensitivity of 63% and a specificity of 72%, whereas the sensitivity and specificity of CA 125 > 35 U ml-1 were 80% and 82% respectively. A combination of the two markers increased the sensitivity to 91% (TATI > 21 ng ml-1 or CA 125 > 35 U ml-1), whereas the specificity decreased to 65%. TATI was clearly superior in diagnosing mucinous carinomata of the ovaries; the rate of true positive findings was 64% versus 50% for CA 125. Unlike CA 125, TATI levels correlated well with tumour grade. In conclusion, CA 125 remains the single tumour marker of choice in the diagnosis of malignant epithelial ovarian cancer, while TATI appears to be a valuable complementory marker with a higher sensitivity in cases of poorly differentiated and mucinous carcinomata.
对180例上皮性卵巢癌患者和214例患有良性盆腔病变的女性测定了血清组织多肽抗原（TATI）水平（临界值为21 ng/ml）和癌抗原125（CA 125）水平（临界值为35 U/ml）。数据与肿瘤分期、组织学类型和肿瘤分级相关。总体而言，当作为单一标志物使用时，TATI的灵敏度为63%，特异度为72%，而CA 125>35 U/ml时的灵敏度和特异度分别为80%和82%。两种标志物联合使用可将灵敏度提高至91%（TATI>21 ng/ml或CA 125>35 U/ml），而特异度降至65%。TATI在诊断卵巢黏液性癌方面明显更具优势；真阳性率为64%，而CA 125为50%。与CA 125不同，TATI水平与肿瘤分级密切相关。总之，CA 125仍然是诊断恶性上皮性卵巢癌的首选单一肿瘤标志物，而TATI似乎是一种有价值的补充标志物，在低分化和黏液性癌病例中具有更高的灵敏度。
